Merrill maintains Altus at buy

Altus Pharmaceuticals Inc. was kept at a buy rating by Merrill Lynch analyst Tom McGahren. The company reported positive phase 2 data for its growth hormone ALTU-238 after the study met its primary objective of safety, tolerability and favorable pharmacokinetic and pharmcodynamic profiles. Altus plans phase 3 trials for later this year. Shares of the Cambridge, Mass.-based pharmaceutical company were up 99 cents, or 5.94%, at $17.67 on volume of 188,865 shares versus the three-month running average of 129,897 shares. (Nasdaq: ALTU)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.